Search company, investor...
IncellDx company logo



Series A - II | Alive

Total Raised


Last Raised

$6M | 11 yrs ago

About IncellDx

InCellDx focuses on the detection and monitoring of life-threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis and organ transplant rejection. The company's technology enables quantification of molecular biomarkers inside intact cells using cell-based instruments and in-situ hybridization. This process allows protein and gene expression to be measured by distinct cell type, aiding in both diagnosis and disease localization.

Headquarters Location

1700 EL Camino Real

Menlo Park, California, 94027,

United States


Missing: IncellDx's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: IncellDx's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing IncellDx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

IncellDx is included in 2 Expert Collections, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

IncellDx Patents

IncellDx has filed 21 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Cytokines
  • Transcription factors
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Cytokines, Clusters of differentiation, Autoimmune diseases, Syndromes


Application Date


Grant Date



Related Topics

Transcription factors, Cytokines, Clusters of differentiation, Autoimmune diseases, Syndromes



Latest IncellDx News

First Diagnostic Test for Long COVID Launches in September

Sep 5, 2022

The first diagnostic test designed to identify patients with long COVID has received CE-IVD marking in Europe. It is ready for its formal launch in countries accepting the designation in September of this year. The simple blood test can help to objectively diagnose patients suffering from Post-Acute Sequelae of COVID-19 (PASC), commonly known as long COVID. Developed by IncellDx, the test will be available to prescribers and patients in September through one of the world’s largest providers of diagnostic services. A CE Mark indicates that the incellKINE Long COVID In Vitro Diagnostic fulfills the requirements of relevant European product directives and meets all the requirements of the relevant recognized European harmonized performance and safety standards. “With so many people in Europe and around the world suffering from ongoing symptoms of COVID, without a diagnosis available to confirm long COVID , we are very pleased to receive the CE Mark, and to be launching long COVID testing in Europe next month,” says Bruce Patterson, MD, CEO of IncellDx. “Together with the support of our own studies to better understand the underlying cause of long COVID and a validation study from a respected global reference lab, this CE IVD mark provides additional validation of the quality and reliability of this diagnostic.” The CE marking is supported by data from a validation study conducted by one of the world’s largest providers of diagnostic services, showing the test provides greater than 90% accuracy across COVID strains. The test was developed based on clinical studies published in the peer reviewed journal Frontiers in Immunology, which showed that IncellDx researchers generated credible, objective disease scores for long COVID using machine learning and artificial intelligence to measure and analyze sets of inflammatory markers called cytokines and chemokines. The studies also demonstrated that patients with previous COVID infection and lingering symptoms were found to have a distinct immunologic profile characterized by patterns of inflammatory marker expression. In a subsequent publication, IncellDx found SARS CoV-2 S1 spike protein in monocytic reservoirs of long COVID patients up to 15 months after acute infection. These papers can be found  here  and  here . “Long COVID presents a significant diagnostic and treatment challenge for patients,” Patterson says. “Many of the symptoms that are associated with long COVID, including fatigue, brain fog, shortness of breath, insomnia, and a wide range of cardiovascular issues, can easily be mistaken for other conditions like post-Lyme, ME-CFS, Fibromyalgia, or even the common cold. Having an effective – and importantly an objective – tool to diagnose the condition is absolutely essential. An objective test that can detect immune signatures specific to long COVID is vital for effective diagnosis and to enable patients to seek effective treatment.” The prevalence of long COVID is thought to be increasing across the U.K. and Europe, with significant impact both to individuals and to the economy. In April, the European Commission said that between 60% and 80% of the EU population was estimated to have been infected with acute COVID-19, while the World Health Organization estimates long COVID affects up to 20% of patients infected with acute COVID. A recent study from the Luxembourg Institute of Health found that six in 10 patients had at least one persistent COVID-19 symptom, and that patients whose symptoms have not resolved by 15 weeks are likely to experience symptoms for at least a year. One in seven participants indicated that they “couldn’t fathom coping with their symptoms long term.” Another study published in May in the Lancet medical journal found that two years after infection, half of people hospitalized with COVID-19 still have at least one symptom. In these studies, the most common symptoms were fatigue, shortness of breath, and irritability. “With an estimated 200 million worldwide suffering, and established negative impact to health systems and economies in Europe, the US, India and South America, long COVID is already becoming the world’s next global public health crisis,” Patterson said. “We are pleased that CE marking was granted for the IncellDx incellKINE long COVID test in Europe, and that the test will be made widely available to physicians and their patients soon.” Share:

IncellDx Frequently Asked Questions (FAQ)

  • Where is IncellDx's headquarters?

    IncellDx's headquarters is located at 1700 EL Camino Real, Menlo Park.

  • What is IncellDx's latest funding round?

    IncellDx's latest funding round is Series A - II.

  • How much did IncellDx raise?

    IncellDx raised a total of $9M.

  • Who are the investors of IncellDx?

    Investors of IncellDx include Bio-Reference Laboratories.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.